Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application

Hepatocellular carcinoma (HCC) is on the rise worldwide, and its incidence in diabetic patients is two to three times that of non-diabetics. Current therapeutic options fail to provide considerable survival benefits to patients with HCC. There is a strong possibility that the FDA-approved antidiabet...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amir Mohamed Abdelhamid, Sameh Saber, Mahmoud E. Youssef, Ahmed Gaafar Ahmed Gaafar, Hanan Eissa, Marwa A. Abd-Eldayem, Mohammed Alqarni, Gaber El-Saber Batiha, Ahmad J. Obaidullah, Mohamed Awad Shahien, Eman El-Ahwany, Noha A. Amin, Mohamed Ali Etman, Mohamed M.Y. Kaddah, Eslam E. Abd El-Fattah
Formato: article
Lenguaje:EN
Publicado: Elsevier 2022
Materias:
Hepatocellular carcinoma
Emagliflozin/metformin
Autophagy
Apoptosis
Angiogenesis
Metastasis
Therapeutics. Pharmacology
RM1-950
Acceso en línea:https://doaj.org/article/243e31ff9d064d9ab4bb5a9d133137d8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/243e31ff9d064d9ab4bb5a9d133137d8

Ejemplares similares